The purpose of the trial is to determine if extended-release dipyridamole + aspirin \[Aggrenox, Asasa ntin\] is superior to clopidogrel \[Plavix\], and if telmisartan \[Micardis, Gliosartan, Kinzal, Kinzalm ono, Predxal, Pritor, Samertan, Telmisartan\] is superior to placebo, in the presence of background antihypertensive therapy, in prevention of a second stroke in patients who have recently suffered a stroke and therefore are at high risk of suffering another one.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Enrollment
20,332
Number of Patients With First Recurrent Stroke of Any Type, Fatal or Nonfatal (Antiplatelet Comparison Only)
Time frame: time since randomization; follow-up period is 1.5 to 4.4 years
Number of Patients With First Recurrent Stroke of Any Type, Fatal or Nonfatal (Telmisartan vs. Placebo Only)
Time frame: time since randomization; follow-up period is 1.5 to 4.4 years
Composite Outcome of Stroke, Myocardial Infarction (MI), or Vascular Death (Antiplatelet Comparison Only)
Number of patients with any of stroke, myocardial infarction, vascular death
Time frame: time since randomization; follow-up period is 1.5 to 4.4 years
Composite Outcome of Stroke, Myocardial Infarction, Vascular Death, or New or Worsening Congestive Heart Failure (CHF) (Telmisartan vs. Placebo Only)
Number of patients with any of stroke, myocardial infarction, vascular death, or new or worsening congestive heart failure
Time frame: time since randomization; follow-up period is 1.5 to 4.4 years
Number of Patients With New Onset of Diabetes (Telmisartan vs. Placebo Only)
Time frame: Randomization to final patient contact
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
placebo
80 mg micardis
80 mg micardis
placebo
placebo
75 mg clopidogrel
75 mg clopidogrel
placebo
placebo
9.159.1101 Boehringer Ingelheim Investigational Site
Birmingham, Alabama, United States
9.159.1173 Boehringer Ingelheim Investigational Site
Huntsville, Alabama, United States
9.159.1058 Boehringer Ingelheim Investigational Site
Mobile, Alabama, United States
9.159.1087 Boehringer Ingelheim Investigational Site
Montgomery, Alabama, United States
9.159.1081 Boehringer Ingelheim Investigational Site
Northport, Alabama, United States
9.159.1022 Boehringer Ingelheim Investigational Site
Phoenix, Arizona, United States
9.159.1133 Boehringer Ingelheim Investigational Site
Phoenix, Arizona, United States
9.159.1149 Boehringer Ingelheim Investigational Site
Phoenix, Arizona, United States
9.159.1137 Boehringer Ingelheim Investigational Site
Tucson, Arizona, United States
9.159.1184 Boehringer Ingelheim Investigational Site
Fayetteville, Arkansas, United States
...and 657 more locations